Medthority· @Medthority · X·· 2 天前评分70
正文 · 原文
#ESMO26
SigVie-002 study: sigvotatug vedotin did not significantly improve OS vs docetaxel in previously treated nonsquamous #NSCLC.
📊 Median OS: 11.9 vs 11.5 months
📊 HR 0.929; P=0.226
Presented by @peters_solange.
#LungCancer #Oncology #OncTwitter #MedEd #MedX #MedSky
33 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Medthority · x.com